ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CD39 Antibody/TGF-beta RII Ectodomain Fusion Protein ES014

Its studies are mostly in Desmoid Tumors · Neoplasm Metastasis, led by 2 companies.

Drug pageAnti-CD39 Antibody/TGF-beta RII Ectodomain Fusion Protein ES014: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Mar 31, 20263 company-led studies, 2 open or runningNext primary completion: Feb 28, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Elpiscience (Suzhou) Biopharmaits history only22 open or runningphase 2since Mar 31, 2026Jan 28, 2023Feb 28, 2027phase 1 · NCT05717348
Elpiscience Biopharmaits history only10 open or runningphase 1since May 11, 2022May 11, 2022none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 11, 2022First study: phase 1 study in Advanced Solid TumorNew to Elpiscience BiopharmaElpiscience Biopharma · NCT05381935
  2. Jan 28, 2023Elpiscience (Suzhou) Biopharma’s first study: phase 1 study in Neoplasm MetastasisNew to Elpiscience (Suzhou) BiopharmaElpiscience (Suzhou) Biopharma · NCT05717348 · 120 enrolled · China
  3. Mar 31, 2026Phase 2 study in Desmoid TumorsPhase 2 reachedElpiscience (Suzhou) Biopharma · NCT07541430 · 50 planned · China

Ahead

  1. Feb 28, 2027Primary completion: phase 1 study in Neoplasm MetastasisElpiscience (Suzhou) Biopharma · NCT05717348
  2. Jan 2028Primary completion: phase 2 study in Desmoid TumorsElpiscience (Suzhou) Biopharma · NCT07541430

TargetBeta

ENTPD1 →read by rule
“A fusion protein composed of a monoclonal antibody directed against the cell surface receptor CD39 (cluster of differentiation 39; ectonucleoside triphosphate diphosphohydrolase-1; NTPDase1; ENTPD1) and ”NCIt, by rule

Other programs on ENTPD1

ProgramCompanyFurthest phaseStudies
Anti-CD39 Monoclonal Antibody IPH5201innate-pharmaphase 22
Anti-PD-1/Anti-CD39 Bispecific Antibody BNT317ruleBioNTechphase 21

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07541430Desmoid Tumors · China2RecruitingElpiscience (Suzhou) BiopharmaJan 202850
NCT05717348Neoplasm Metastasis · China1Active, not recruitingElpiscience (Suzhou) BiopharmaFeb 28, 2027120
NCT05381935Advanced Solid Tumor1WithdrawnElpiscience BiopharmaApr 30, 20260

How it is read

Names in the registry

  • “ES014”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.